Exxon Mobil was upgraded by Bank of America Merrill Lynch and the raised price target caused stocks to get a lift in the morning session. However, the boost did not last long and stocks began to give back those gains. Ben Willis of Albert Fried notes many stocks being sold are ones with high margin requirements. Willis mostly sees a sector rotation happening out of the names and going into lower beta names. He also points out the biotech weakness at NASDAQ.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Video

Need Some Income for Your Portfolio? Consider Closed-End Funds

Need Some Income for Your Portfolio? Consider Closed-End Funds

Is the Cannabis Crazy Equivalent to the Dot Com Bubble?

Is the Cannabis Crazy Equivalent to the Dot Com Bubble?

Closed-End Fund (CEF) Distributions, What You Need to Know

Closed-End Fund (CEF) Distributions, What You Need to Know

Former GE Exec Beth Comstock Reveals This Dire Change Companies Need to Make

Former GE Exec Beth Comstock Reveals This Dire Change Companies Need to Make

60 Seconds: The Documents You Need in a Disaster

60 Seconds: The Documents You Need in a Disaster